|
|
Prepublished online as a Blood First Edition Paper on April 24, 2003; DOI 10.1182/blood-2003-01-0019.
Previous Article | Table of Contents | Next Article 
Blood, 15 August 2003, Vol. 102, No. 4, pp. 1389-1396
IMMUNOBIOLOGY
Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia
Helmut Rainer Salih,
Holger Antropius,
Friederike Gieseke,
Stefan Zoltan Lutz,
Lothar Kanz,
Hans-Georg Rammensee, and
Alexander Steinle
From the Department of Internal Medicine II, University Hospital, Eberhard-Karls-University, Tübingen, Germany; and Department of Immunology, Eberhard-Karls-University, Tübingen, Germany
NKG2D ligands (NKG2DLs) mark malignant cells for recognition by natural killer (NK) cells and cytotoxic T lymphocytes via the activating immunoreceptor NKG2D. This led to the hypothesis that NKG2DLs play a critical role in tumor immune surveillance. The human NKG2DLs MICA and MICB are expressed on tumors of epithelial origin in vivo. For the other recently described set of human NKG2DLs, the UL16-binding proteins (ULBPs), expression in vivo is as yet undefined. In this study we investigated expression and function of NKG2DLs in leukemia using a panel of newly generated NKG2DL-specific monoclonal antibodies. We report that leukemia cells from patients variously express MIC and ULBP molecules on the cell surface with MICA most frequently detected. Patient leukemia cells expressing MICA were lysed by NK cells in an NKG2D-dependent fashion. Sera of patients, but not of healthy donors, contained elevated levels of soluble MICA (sMICA). We also detected increased sMICB levels in patient sera using a newly established MICB-specific enzyme-linked immunosorbent assay. Reduction of leukemia MIC surface expression by shedding may impair NKG2D-mediated immune surveillance of leukemias. In addition, determination of sMICA and sMICB levels may be implemented as a prognostic parameter in patients with hematopoietic malignancies.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. W. McGilvray, R. A. Eagle, N. F.S. Watson, A. Al-Attar, G. Ball, I. Jafferji, J. Trowsdale, and L. G. Durrant
NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for Immunoediting
Clin. Cancer Res.,
November 15, 2009;
15(22):
6993 - 7002.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Langenkamp, U. Siegler, S. Jorger, S. Diermayr, A. Gratwohl, C. P. Kalberer, and A. Wodnar-Filipowicz
Human acute myeloid leukemia CD34+CD38- stem cells are susceptible to allorecognition and lysis by single KIR-expressing natural killer cells
Haematologica,
November 1, 2009;
94(11):
1590 - 1594.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Kohga, T. Takehara, T. Tatsumi, T. Miyagi, H. Ishida, K. Ohkawa, T. Kanto, N. Hiramatsu, and N. Hayashi
Anticancer Chemotherapy Inhibits MHC Class I-Related Chain A Ectodomain Shedding by Downregulating ADAM10 Expression in Hepatocellular Carcinoma
Cancer Res.,
October 15, 2009;
69(20):
8050 - 8057.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-G. Kopp, T. Placke, and H. R. Salih
Platelet-Derived Transforming Growth Factor-{beta} Down-Regulates NKG2D Thereby Inhibiting Natural Killer Cell Antitumor Reactivity
Cancer Res.,
October 1, 2009;
69(19):
7775 - 7783.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Paschen, A. Sucker, B. Hill, I. Moll, M. Zapatka, X. D. Nguyen, G. C. Sim, I. Gutmann, J. Hassel, J. C. Becker, et al.
Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B
Clin. Cancer Res.,
August 15, 2009;
15(16):
5208 - 5215.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hedlund, A.-C. Stenqvist, O. Nagaeva, L. Kjellberg, M. Wulff, V. Baranov, and L. Mincheva-Nilsson
Human Placenta Expresses and Secretes NKG2D Ligands via Exosomes that Down-Modulate the Cognate Receptor Expression: Evidence for Immunosuppressive Function
J. Immunol.,
July 1, 2009;
183(1):
340 - 351.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Roda-Navarro and H. T. Reyburn
The Traffic of the NKG2D/Dap10 Receptor Complex during Natural Killer (NK) Cell Activation
J. Biol. Chem.,
June 12, 2009;
284(24):
16463 - 16472.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Lundqvist, H. Yokoyama, A. Smith, M. Berg, and R. Childs
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells
Blood,
June 11, 2009;
113(24):
6120 - 6127.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Butler, M. B. Moore, S. R. Presnell, H.-W. Chan, N. J. Chalupny, and C. T. Lutz
Proteasome Regulation of ULBP1 Transcription
J. Immunol.,
May 15, 2009;
182(10):
6600 - 6609.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Cerboni, M. Ardolino, A. Santoni, and A. Zingoni
Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells
Blood,
March 26, 2009;
113(13):
2955 - 2964.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Charni, J. I. Aguilo, J. Garaude, G. de Bettignies, C. Jacquet, R. A. Hipskind, D. Singer, A. Anel, and M. Villalba
ERK5 Knockdown Generates Mouse Leukemia Cells with Low MHC Class I Levels That Activate NK Cells and Block Tumorigenesis
J. Immunol.,
March 15, 2009;
182(6):
3398 - 3405.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Boutet, S. Aguera-Gonzalez, S. Atkinson, C. J. Pennington, D. R. Edwards, G. Murphy, H. T. Reyburn, and M. Vales-Gomez
Cutting Edge: The Metalloproteinase ADAM17/TNF-{alpha}-Converting Enzyme Regulates Proteolytic Shedding of the MHC Class I-Related Chain B Protein
J. Immunol.,
January 1, 2009;
182(1):
49 - 53.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kloss, P. Decker, K. M. Baltz, T. Baessler, G. Jung, H.-G. Rammensee, A. Steinle, M. Krusch, and H. R. Salih
Interaction of Monocytes with NK Cells upon Toll-Like Receptor-Induced Expression of the NKG2D Ligand MICA
J. Immunol.,
November 15, 2008;
181(10):
6711 - 6719.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Germain, E. Campigna, I. Salhi, S. Morisseau, I. Navarro-Teulon, J.-P. Mach, A. Pelegrin, and B. Robert
Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein
Protein Eng. Des. Sel.,
November 1, 2008;
21(11):
665 - 672.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Waldhauer, D. Goehlsdorf, F. Gieseke, T. Weinschenk, M. Wittenbrink, A. Ludwig, S. Stevanovic, H.-G. Rammensee, and A. Steinle
Tumor-Associated MICA Is Shed by ADAM Proteases
Cancer Res.,
August 1, 2008;
68(15):
6368 - 6376.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Cao, X. Xi, Z. Wang, L. Dong, Z. Hao, L. Cui, C. Ma, and W. He
Four novel ULBP splice variants are ligands for human NKG2D
Int. Immunol.,
August 1, 2008;
20(8):
981 - 991.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Dulphy, P. Haas, M. Busson, S. Belhadj, R. Peffault de Latour, M. Robin, M. Carmagnat, P. Loiseau, R. Tamouza, C. Scieux, et al.
An Unusual CD56brightCD16low NK Cell Subset Dominates the Early Posttransplant Period following HLA-Matched Hematopoietic Stem Cell Transplantation
J. Immunol.,
August 1, 2008;
181(3):
2227 - 2237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Iannello, O. Debbeche, S. Samarani, and A. Ahmad
Antiviral NK cell responses in HIV infection: I. NK cell receptor genes as determinants of HIV resistance and progression to AIDS
J. Leukoc. Biol.,
July 1, 2008;
84(1):
1 - 26.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Iannello, O. Debbeche, S. Samarani, and A. Ahmad
Antiviral NK cell responses in HIV infection: II. viral strategies for evasion and lessons for immunotherapy and vaccination
J. Leukoc. Biol.,
July 1, 2008;
84(1):
27 - 49.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Le Maux Chansac, D. Misse, C. Richon, I. Vergnon, M. Kubin, J.-C. Soria, A. Moretta, S. Chouaib, and F. Mami-Chouaib
Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway
Int. Immunol.,
July 1, 2008;
20(7):
801 - 810.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Armeanu, M. Krusch, K. M. Baltz, T. S. Weiss, I. Smirnow, A. Steinle, U. M. Lauer, M. Bitzer, and H. R. Salih
Direct and Natural Killer Cell-Mediated Antitumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma
Clin. Cancer Res.,
June 1, 2008;
14(11):
3520 - 3528.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Vales-Gomez, S. E. Chisholm, R. L. Cassady-Cain, P. Roda-Navarro, and H. T. Reyburn
Selective Induction of Expression of a Ligand for the NKG2D Receptor by Proteasome Inhibitors
Cancer Res.,
March 1, 2008;
68(5):
1546 - 1554.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Diermayr, H. Himmelreich, B. Durovic, A. Mathys-Schneeberger, U. Siegler, U. Langenkamp, J. Hofsteenge, A. Gratwohl, A. Tichelli, M. Paluszewska, et al.
NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities
Blood,
February 1, 2008;
111(3):
1428 - 1436.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-J. Kim, M.-K. Han, and H. E. Broxmeyer
4-1BB regulates NKG2D costimulation in human cord blood CD8+ T cells
Blood,
February 1, 2008;
111(3):
1378 - 1386.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. I. Marusina, S. J. Burgess, I. Pathmanathan, F. Borrego, and J. E. Coligan
Regulation of Human DAP10 Gene Expression in NK and T Cells by Ap-1 Transcription Factors
J. Immunol.,
January 1, 2008;
180(1):
409 - 417.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Maccalli, D. Nonaka, A. Piris, D. Pende, L. Rivoltini, C. Castelli, and G. Parmiani
NKG2D-Mediated Antitumor Activity by Tumor-Infiltrating Lymphocytes and Antigen-Specific T-Cell Clones Isolated from Melanoma Patients
Clin. Cancer Res.,
December 15, 2007;
13(24):
7459 - 7468.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Zhang, A. Barber, and C. L. Sentman
Chimeric NKG2D Modified T Cells Inhibit Systemic T-Cell Lymphoma Growth in a Manner Involving Multiple Cytokines and Cytotoxic Pathways
Cancer Res.,
November 15, 2007;
67(22):
11029 - 11036.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. V. Girart, M. B. Fuertes, C. I. Domaica, L. E. Rossi, and N. W. Zwirner
Engagement of TLR3, TLR7, and NKG2D Regulate IFN-{gamma} Secretion but Not NKG2D-Mediated Cytotoxicity by Human NK Cells Stimulated with Suboptimal Doses of IL-12
J. Immunol.,
September 15, 2007;
179(6):
3472 - 3479.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. M. Baltz, M. Krusch, A. Bringmann, P. Brossart, F. Mayer, M. Kloss, T. Baessler, I. Kumbier, A. Peterfi, S. Kupka, et al.
Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions
FASEB J,
August 1, 2007;
21(10):
2442 - 2454.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Cao, X. Xi, Z. Hao, W. Li, Y. Kong, L. Cui, C. Ma, D. Ba, and W. He
RAET1E2, a Soluble Isoform of the UL16-binding Protein RAET1E Produced by Tumor Cells, Inhibits NKG2D-mediated NK Cytotoxicity
J. Biol. Chem.,
June 29, 2007;
282(26):
18922 - 18928.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Roda-Navarro and H. T. Reyburn
Intercellular protein transfer at the NK cell immune synapse: mechanisms and physiological significance
FASEB J,
June 1, 2007;
21(8):
1636 - 1646.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. K. Epling-Burnette, F. Bai, J. S. Painter, D. E. Rollison, H. R. Salih, M. Krusch, J. Zou, E. Ku, B. Zhong, D. Boulware, et al.
Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors
Blood,
June 1, 2007;
109(11):
4816 - 4824.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Barber, T. Zhang, L. R. DeMars, J. Conejo-Garcia, K. F. Roby, and C. L. Sentman
Chimeric NKG2D Receptor-Bearing T Cells as Immunotherapy for Ovarian Cancer
Cancer Res.,
May 15, 2007;
67(10):
5003 - 5008.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Catellani, A. Poggi, A. Bruzzone, P. Dadati, J. L. Ravetti, M. Gobbi, and M. R. Zocchi
Expansion of V{delta}1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins
Blood,
March 1, 2007;
109(5):
2078 - 2085.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Saikali, J. P. Antel, J. Newcombe, Z. Chen, M. Freedman, M. Blain, R. Cayrol, A. Prat, J. A. Hall, and N. Arbour
NKG2D-Mediated Cytotoxicity toward Oligodendrocytes Suggests a Mechanism for Tissue Injury in Multiple Sclerosis
J. Neurosci.,
January 31, 2007;
27(5):
1220 - 1228.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Osaki, H. Saito, T. Yoshikawa, S. Matsumoto, S. Tatebe, S. Tsujitani, and M. Ikeguchi
Decreased NKG2D Expression on CD8+ T Cell Is Involved in Immune Evasion in Patients with Gastric Cancer
Clin. Cancer Res.,
January 15, 2007;
13(2):
382 - 387.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Cerboni, F. Neri, N. Casartelli, A. Zingoni, D. Cosman, P. Rossi, A. Santoni, and M. Doria
Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity
J. Gen. Virol.,
January 1, 2007;
88(1):
242 - 250.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Mura, M. Pfeiffer, R. Handgretinger, and P. J. Lang
Expression of Activating Natural Killer Cell Receptor Ligands in Childhood Acute Lymphoblastic Leukemia.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
4478 - 4478.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Trichet, C. Benezech, C. Dousset, M.-C. Gesnel, M. Bonneville, and R. Breathnach
Complex Interplay of Activating and Inhibitory Signals Received by V{gamma}9V{delta}2 T Cells Revealed by Target Cell beta2-Microglobulin Knockdown
J. Immunol.,
November 1, 2006;
177(9):
6129 - 6136.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Lopez-Soto, A. Quinones-Lombrana, R. Lopez-Arbesu, C. Lopez-Larrea, and S. Gonzalez
Transcriptional Regulation of ULBP1, a Human Ligand of the NKG2D Receptor
J. Biol. Chem.,
October 13, 2006;
281(41):
30419 - 30430.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Spreu, T. Stehle, and A. Steinle
Human Cytomegalovirus-Encoded UL16 Discriminates MIC Molecules by Their {alpha}2 Domains.
J. Immunol.,
September 1, 2006;
177(5):
3143 - 3149.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Eisele, J. Wischhusen, M. Mittelbronn, R. Meyermann, I. Waldhauer, A. Steinle, M. Weller, and M. A. Friese
TGF-{beta} and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells
Brain,
September 1, 2006;
129(9):
2416 - 2425.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Zhang, A. Barber, and C. L. Sentman
Generation of Antitumor Responses by Genetic Modification of Primary Human T Cells with a Chimeric NKG2D Receptor
Cancer Res.,
June 1, 2006;
66(11):
5927 - 5933.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Gasser and D. H. Raulet
The DNA damage response arouses the immune system.
Cancer Res.,
April 15, 2006;
66(8):
3959 - 3962.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Boissel, D. Rea, V. Tieng, N. Dulphy, M. Brun, J.-M. Cayuela, P. Rousselot, R. Tamouza, P. Le Bouteiller, F.-X. Mahon, et al.
BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.
J. Immunol.,
April 15, 2006;
176(8):
5108 - 5116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Mincheva-Nilsson, O. Nagaeva, T. Chen, U. Stendahl, J. Antsiferova, I. Mogren, J. Hernestal, and V. Baranov
Placenta-Derived Soluble MHC Class I Chain-Related Molecules Down-Regulate NKG2D Receptor on Peripheral Blood Mononuclear Cells during Human Pregnancy: A Possible Novel Immune Escape Mechanism for Fetal Survival
J. Immunol.,
March 15, 2006;
176(6):
3585 - 3592.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Waldhauer and A. Steinle
Proteolytic Release of Soluble UL16-Binding Protein 2 from Tumor Cells.
Cancer Res.,
March 1, 2006;
66(5):
2520 - 2526.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. P. von Strandmann, H. P. Hansen, K. S. Reiners, R. Schnell, P. Borchmann, S. Merkert, V. R. Simhadri, A. Draube, M. Reiser, I. Purr, et al.
A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
Blood,
March 1, 2006;
107(5):
1955 - 1962.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. J. Burgess, A. I. Marusina, I. Pathmanathan, F. Borrego, and J. E. Coligan
IL-21 Down-Regulates NKG2D/DAP10 Expression on Human NK and CD8+ T Cells
J. Immunol.,
February 1, 2006;
176(3):
1490 - 1497.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Hanaoka, T. Kawaguchi, K. Horikawa, S. Nagakura, H. Mitsuya, and H. Nakakuma
Immunoselection by natural killer cells of PIGA mutant cells missing stress-inducible ULBP
Blood,
February 1, 2006;
107(3):
1184 - 1191.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Skov, M. T. Pedersen, L. Andresen, P. Thor Straten, A. Woetmann, and N. Odum
Cancer Cells Become Susceptible to Natural Killer Cell Killing after Exposure to Histone Deacetylase Inhibitors Due to Glycogen Synthase Kinase-3-Dependent Expression of MHC Class I-Related Chain A and B
Cancer Res.,
December 1, 2005;
65(23):
11136 - 11145.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Sconocchia, M. Lau, M. Provenzano, K. Rezvani, W. Wongsena, H. Fujiwara, N. Hensel, J. Melenhorst, J. Li, S. Ferrone, et al.
The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions
Blood,
November 15, 2005;
106(10):
3666 - 3672.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Germain, C. Larbouret, V. Cesson, A. Donda, W. Held, J.-P. Mach, A. Pelegrin, and B. Robert
MHC Class I-Related Chain A Conjugated to Antitumor Antibodies Can Sensitize Tumor Cells to Specific Lysis by Natural Killer Cells
Clin. Cancer Res.,
October 15, 2005;
11(20):
7516 - 7522.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Smyth, J. Swann, E. Cretney, N. Zerafa, W. M. Yokoyama, and Y. Hayakawa
NKG2D function protects the host from tumor initiation
J. Exp. Med.,
September 6, 2005;
202(5):
583 - 588.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Girlanda, C. Fortis, D. Belloni, E. Ferrero, P. Ticozzi, C. Sciorati, M. Tresoldi, A. Vicari, T. Spies, V. Groh, et al.
MICA Expressed by Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance Plasma Cells Costimulates Pamidronate-Activated {gamma}{delta} Lymphocytes
Cancer Res.,
August 15, 2005;
65(16):
7502 - 7508.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Rincon-Orozco, V. Kunzmann, P. Wrobel, D. Kabelitz, A. Steinle, and T. Herrmann
Activation of V{gamma}9V{delta}2 T Cells by NKG2D
J. Immunol.,
August 15, 2005;
175(4):
2144 - 2151.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Armeanu, M. Bitzer, U. M. Lauer, S. Venturelli, A. Pathil, M. Krusch, S. Kaiser, J. Jobst, I. Smirnow, A. Wagner, et al.
Natural Killer Cell-Mediated Lysis of Hepatoma Cells via Specific Induction of NKG2D Ligands by the Histone Deacetylase Inhibitor Sodium Valproate
Cancer Res.,
July 15, 2005;
65(14):
6321 - 6329.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Terme, C. Borg, F. Guilhot, C. Masurier, C. Flament, E. F. Wagner, S. Caillat-Zucman, A. Bernheim, A. G. Turhan, A. Caignard, et al.
BCR/ABL Promotes Dendritic Cell-Mediated Natural Killer Cell Activation
Cancer Res.,
July 15, 2005;
65(14):
6409 - 6417.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Wiemann, H.-W. Mittrucker, U. Feger, S. A. Welte, W. M. Yokoyama, T. Spies, H.-G. Rammensee, and A. Steinle
Systemic NKG2D Down-Regulation Impairs NK and CD8 T Cell Responses In Vivo
J. Immunol.,
July 15, 2005;
175(2):
720 - 729.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. C. Hsu, C. A. Keever-Taylor, A. Wilton, C. Pinto, G. Heller, K. Arkun, R. J. O'Reilly, M. M. Horowitz, and B. Dupont
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes
Blood,
June 15, 2005;
105(12):
4878 - 4884.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Groh, Y. Q. Li, D. Cioca, N. N. Hunder, W. Wang, S. R. Riddell, C. Yee, and T. Spies
From The Cover: Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells
PNAS,
May 3, 2005;
102(18):
6461 - 6466.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Nowbakht, M.-C. S. Ionescu, A. Rohner, C. P. Kalberer, E. Rossy, L. Mori, D. Cosman, G. De Libero, and A. Wodnar-Filipowicz
Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias
Blood,
May 1, 2005;
105(9):
3615 - 3622.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Pende, G. M. Spaggiari, S. Marcenaro, S. Martini, P. Rivera, A. Capobianco, M. Falco, E. Lanino, I. Pierri, R. Zambello, et al.
Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)
Blood,
March 1, 2005;
105(5):
2066 - 2073.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Poggi, C. Venturino, S. Catellani, M. Clavio, M. Miglino, M. Gobbi, A. Steinle, P. Ghia, S. Stella, F. Caligaris-Cappio, et al.
V{delta}1 T Lymphocytes from B-CLL Patients Recognize ULBP3 Expressed on Leukemic B Cells and Up-Regulated by Trans-Retinoic Acid
Cancer Res.,
December 15, 2004;
64(24):
9172 - 9179.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. R. Salih, P. Stieber, A. Peterfi, D. Nagel, L. Kanz, A. L. Steinle, and S. Holdenrieder
Determination of Soluble MICA in Serum as a Novel Marker for Tumor Stage and Metastasis.
Blood (ASH Annual Meeting Abstracts),
November 16, 2004;
104(11):
1344 - 1344.
[Abstract]
|
 |
|

|
 |

|
 |
 
M. J. Smyth, J. Swann, J. M. Kelly, E. Cretney, W. M. Yokoyama, A. Diefenbach, T. J. Sayers, and Y. Hayakawa
NKG2D Recognition and Perforin Effector Function Mediate Effective Cytokine Immunotherapy of Cancer
J. Exp. Med.,
November 15, 2004;
200(10):
1325 - 1335.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Igarashi, J. Wynberg, R. Srinivasan, B. Becknell, J. P. McCoy Jr, Y. Takahashi, D. A. Suffredini, W. M. Linehan, M. A. Caligiuri, and R. W. Childs
Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells
Blood,
July 1, 2004;
104(1):
170 - 177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. R. Verneris, M. Karami, J. Baker, A. Jayaswal, and R. S. Negrin
Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells
Blood,
April 15, 2004;
103(8):
3065 - 3072.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Ferlazzo and C. Munz
NK Cell Compartments and Their Activation by Dendritic Cells
J. Immunol.,
February 1, 2004;
172(3):
1333 - 1339.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. S. Doubrovina, M. M. Doubrovin, E. Vider, R. B. Sisson, R. J. O'Reilly, B. Dupont, and Y. M. Vyas
Evasion from NK Cell Immunity by MHC Class I Chain-Related Molecules Expressing Colon Adenocarcinoma
J. Immunol.,
December 15, 2003;
171(12):
6891 - 6899.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|